Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / @xirurgi_2025 / @xirurgi_2025 - 978 - файл

.pdf
Скачиваний:
0
Добавлен:
29.08.2026
Размер:
7 Мб
Скачать
38 Classifications and Lists in Oral and Maxillofacial Surgery
https://t.me/med1917
INVESTIGATIONS FOR A CARCINOMA OFUNKNOWN PRIMARY (CUP) ORIGIN
e following list outlines investigations which can aid the diag­nosis of carcinoma of unknown primary origin.
1. Whole-body PET-CT
2. Pan-endoscopy and biopsy of PNS/tongue base/piriform (or pyriform) fossae (under 50% hit rate) and, if available, tongue base mucosectomy with TORS (50% hit rate)
3. Bilateral tonsillectomy
4. MRI (if level 2/3 node), for example, skull base to clavicles
LIP DEFECT TYPES AND RECONSTRUCTION OPTIONS
e following list outlines common types of lip defects following oncological resection and various reconstruction options
Less than half of either lip – wedge excision and primary closure
Half to two-thirds of lower lip – Karapandzic, reverse Abbe­Estlander, Johannsen step, Schuchart
Half to two-thirds of upper lip – perialar crescenteric, Abbe­Estlander, reverse Karapandzic
More than two-thirds of lower lip – Gillies’ fan aps/ McGregor’s aps/Nakajima’s aps (preserved facial artery), Webster aps, gate aps, free ap
More than two-thirds of upper lip – Burrow-Dienbach (bilateral perialar cresenteric), free ap
.
NB: Microstomia should be managed with Karapandzic and Gillies’ aps as they are advancement aps, but at least they retain muscle sphincter and, therefore, oral continence (McGregor and Nakajima do not retain oral continence).
t.me/Dr_Mouayyad_AlbtousH
Head and Neck Oncology 39
https://t.me/med1917
LYMPHOMA STAGING
e following list describes how the extent of lymphoma spread can be ascertained.
1. Single node
2. Two or more nodes SAME side diaphragm
3. Both sides diaphragm
4. Extralymphatic
+B symptoms: 10% unintentional weight loss, fever, night sweats
Stage 1 or 2 (A) get DXT
B symptoms or stage 3 and higher, get CHOP regimen (cyclophosphamide, doxorubicin, vincristine sulphate, prednisolone) ± rituximab (anti-CD20 on b cells)
MATHES AND NAHAI CLASSIFICATION OF MUSCULAR FLAPS
is classication describes the patterns of blood supply and perfusion in musculocutaneous free aps. Also listed here are examples of muscles corresponding to dierent vascular patterns.
1. Single dominant pedicle (tensor fasciae lata)
2. Dominant and minor pedicle (gracilis medial femoral cir­cumex and deep branch)
3. Two dominants (rectus abdominis)
4. Segmental (sartorius)
5. Dominant with secondary segmentals (pectoralis major, latis­simus dorsi)
t.me/Dr_Mouayyad_AlbtousH
40 Classifications and Lists in Oral and Maxillofacial Surgery
https://t.me/med1917
NODE STAGING
e following list describes patterns of nodal spread of head and neck malignancy.
N1 – single ipsilateral node up to 3cm
N2a – single ipsilateral node up to 6cm
N2b – two ipsilateral nodes up to 6cm
N2c – contralateral or bilateral nodes up to 6cm
N3a – Anode more than 6cm
N3b – extra-nodal spread (tethering/nerve involvement)
ORAL (AND OROPHARYNGEAL) CANCER TUMOUR, NODE, METASTASIS (TNM)
e system outlined next describes the tumour component of the TNM classication. A higher T classication corresponds to invasion of local and more distant structures, as well as to a greater size of tumour and increased depth of invasion.
T1 – up to 2cm (and depth of invasion up to 0.5cm)
T2 – up to 4cm (and depth of invasion up to 1 cm)
T3 – more than 4cm (or depth of invasion more than 1cm; or onto lingual epiglottis in oropharyngeal)
T4a – includes local structures (medial pterygoid, larynx, muscles of tongue, palate, mandible)
T4b – includes more distant structures (lateral pterygoid, pterygoid plates, lateral nasopharynx, skull base, carotids)
OSTEORADIONECROSIS (ORN) GRADESBYNOTANI
e classication that follows describes extent of osteoradio­necrosis of the mandible according to extension of the lesion into the medullary bone below or above the inferior dental (ID) canal. Ahigher grade denotes extension into the medulla below the ID canal and an associated fracture or stula.
t.me/Dr_Mouayyad_AlbtousH
Head and Neck Oncology 41
https://t.me/med1917
1. Alveolar
2. Into medulla above ID canal
3. Into medulla below ID canal (±fracture/stula)
ORN STAGES BY MARX
e classication that follows describes stages of osteoradione­crosis according to depth of bone damage and response to hyper­baric oxygen (HBO). e most advanced stage requires complete surgical resection and reconstruction.
Stage I – exposed alveolar bone without pathological fracture, responds to HBO therapy
Stage II – disease does not respond to HBO therapy, requires sequestrectomy and saucerisation
Stage III – full-thickness bone damage or pathological frac­ture, requires complete resection and reconstruction with free aps/tissue
ORN TYPES BY LYONS ET AL.
is system describes osteoradionecrosis in terms of the size of the bone exposed and whether the exposure is symptomatic. Debridement and local ap reconstruction can be employed to manage symptomatic patients. Complications from primary disease require free ap reconstruction and ORIF (in case of pathological fracture).
1. <2.5cm bone exposed, asymptomatic
2. >2.5cm, asymptomatic (even if fracture)
ese get medical treatment only, unless sepsis or loose necroticbone.
3. Symptomatic, debride and local ap
4. Complications (stula, fracture, IAN symptoms), ORIF and free ap reconstruction
t.me/Dr_Mouayyad_AlbtousH
42 Classifications and Lists in Oral and Maxillofacial Surgery
https://t.me/med1917
RESPONSE EVALUATION CRITERIA IN SOLID TUMOURS (RECIST)
e criteria that follow help to evaluate the treatment response of solid tumours.
CR – disappearance of all target lesions
PR – 30% reduction in sum of target lesions
PD – 20% increase
SD – small changes not meeting criteria
RESIDUAL TUMOUR CLASSIFICATION
e following classication describes the extent of residual tumour following resection/treatment. Ahigher R grade is asso­ciated with visible residual pathology.
R0 – curative resection
R1 – microscopic residual disease
R2 – macroscopic residual disease
SHAMBLIN’S CLASSIFICATION OF CAROTID BODY TUMOURS
is system describes the management of carotid body tumours based on their size.
1. Small and easy to resect (≤180 degrees circumferential contact)
2. Medium/adherent (181–269 degrees)
3. Large (transmural), needs resection and gra (≥270 degrees)
SINO-NASAL TNM
e system that follows describes the substages of the tumour component of TNM classication of sino-nasal malignancy.
T1 – mucosa only
T2 – bone invasion (not posterior wall antrum or pterygoid)
t.me/Dr_Mouayyad_AlbtousH
Head and Neck Oncology 43
https://t.me/med1917
T3 – into posterior wall antrum/SC tissues, oor and medial wall orbit, ethmoids, pterygoid fossa
T4a – into pterygoid plates/anterior orbit, cheek skin, infra­temporal fossa, cribriform plate, sphenoid/frontal sinus
T4b – into orbital apex, dura/brain, middle cranial fossa, nasopharynx, clivus, cranial nerves other than V2 (maxillary branch of the trigeminal nerve)
SINO-NASAL TUMOUR MANAGEMENT
e following summary provides an overview of management strategies, surgical access and approach considerations for sino­nasal tumours.
Craniofacial approach usually (but endoscopic possible with small tumours of lateral nasal wall and anterior skull base). ree types: type 1, transorbital (lynch and lateral rhi­notomy); type 2, shield; type 3, lateral rhinotomy and frontal craniotomy. All need excision and radiotherapy; elective neck dissection for T3/T4, but not for small, low-grade tumours; lifelong follow-up needed for T3/T4 as dicult to monitor.
Ohngren’s line – plane drawn between the medial canthus and angle of mandible, can be combined with a midpupillary plane, antero-inferomedial sino-nasal malignancies have the best prog­nosis, postero-superomedial ones have the most unfavourable.
WHEN TO USE PET-CT
Criteria outlined here describe when positron emission tomog­raphy-computerised tomography (PET-CT) is indicated in the management of head and neck tumours.
Check for recurrence (12 weeks aer DXT/6 weeks aer sur­gery) – sensitive but poor
Specicity when post-operative inammatory changes still present
Carcinoma of unknown primary
Staging of T4 hypopharynx/nasopharynx and N3
t.me/Dr_Mouayyad_AlbtousH
44 Classifications and Lists in Oral and Maxillofacial Surgery
https://t.me/med1917
WHEN TO USE FROZEN SECTION – THREE POINTS
e following list describes when to use frozen sections in the management of head and neck cancers.
Doubt over margins
To conrm diagnosis of benign disease
Lymph node involvement in thyroid cancer
FURTHER READING
Anneroth G, Batsakis J, Luna M. Review of the literature and a
recommended system of malignancy grading in oral squa­mous cell carcinomas. Scand J Dent Res. 1987;95:229–49.
Baumann D, Robb G. Lip reconstruction. Semin Plast Surg.
2008;22(4):269–80. doi: 10.1055/s-0028-1095886.
Brown JS, Barry C, Ho M, Shaw R. Anew classification for man-
dibular defects after oncological resection. Lancet Oncol. 2016;17(1):e23–30.
Byun SH, Lim HK, Yang BE, Kim SM, Lee JH. Delayed reconstruc-
tion of palatomaxillary defect using fibula free flap. J Clin Med. 2020;9(3):884.
Cheson BD, Fisher RI, Barrington SF, etal. Recommendations
for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classifica­tion. J Clin Oncol. 2014;32(27):3059–68.
Dhawan A. Adjunctive therapy in oral cancer. In: Bonanthaya
K,Panneerselvam E, Manuel S, Kumar VV, Rai A, eds. Oral and maxillofacial surgery for the clinician. Singapore: Springer; 2021.
Diagnosis and management of metastatic malignant disease of
unknown primary origin. n.d. www.nice.org.uk/guidance/ cg104/documents/metastatic-malignant-disease-of-unknown­primary-origin-prepublication-check-full-guideline2.
Ganeshalingam S, Koh DM. Nodal staging. Cancer Imaging.
2009;9(1):104–11.
Gastman BR, Mehta AR, Myers JN. Head and neck cancer.
In: Weinzweig J, ed. Plastic surgery secrets plus. 2nd ed. London: Elsevier; 2010: 355–62.
t.me/Dr_Mouayyad_AlbtousH
Head and Neck Oncology 45
https://t.me/med1917
Limaiem F, Davis DD, Sticco KL. Chondrosarcoma [Updated 2023
Jan 1]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023.
Lyons A, Osher J, Warner E, Kumar R, Brennan PA.
Osteoradionecrosis—a review of current concepts in defining the extent of the disease and a new classification proposal. Br J Oral Maxillofac Surg. 2014;52(5):392–95.
Malloy K. AJCC 8th edition major updates in cancer staging:
Implications for OPC treatment? [online]. 2017. www.ahns. info/wp-content/uploads/2017/07/AJCC-8th-Edition-Major­Updates-in-Cancer-Staging.pdf.
Marechek A, AlShare A, Pack S, Demko C, Quereshy FA, Baur D.
Nonvascularized bone grafts for reconstruction of segmental mandibular defects: Is length of graft a factor of success? J Oral Maxillofac Surg. 2019;77(12):2557–66.
Marx RE. Anew concept in the treatment of osteoradionecrosis.
J Oral Maxillofac Surg. 1983;41(6):351–7.
Mathes SJ, Nahai F. Classification of the vascular anatomy of
muscles: Experimental and clinical correlation. Plast Reconstr Surg. 1981;67(2):177–87.
Notani K, Yamazaki Y, Kitada H, Sakakibara N, Nakamura M.
Management of mandibular osteoradionecrosis and the method of radiotherapy. Head Neck. 2003;25: 181–6.
Riemenschnitter CE, Morand GB, Schouten CS, etal. Need
for adjuvant radiotherapy in oral cancer: Depth of invasion rather than tumor diameter. Eur Arch Otorhinolaryngol. 2023;280(1):339–46.
Schwartz LH, Litière S, de Vries E, etal. Recist 1.1-update and
clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–7.
Shamblin WR, ReMine WH, Sheps SG, Harrison EG Jr. Carotid
body tumor (chemodectoma). Clinicopathologic analy­sis of ninety cases. Am J Surg. 1971;122(6):732–9. doi:
10.1016/0002-9610(71)90436-3.
Zanoni DK, Patel SG, Shah JP. Changes in the 8th Edition of the
American Joint Committee on Cancer (AJCC) staging of head and neck cancer: Rationale and implications. Curr Oncol Rep. 2019;21(6):52.
t.me/Dr_Mouayyad_AlbtousH
5
https://t.me/med1917
Salivary Gland Disease
SJÖGREN’S DIAGNOSIS CRITERIA – AMERICAN-EUROPEAN CONSENSUS GROUP(AECG) 2002
e following list outlines diagnostic criteria for Sjögren’s dis­ease according to the AECG (2002); four or more of the six crite­ria are required together with at least one of them being labial gland biopsy/auto-antibodies.
1. Eye symptoms
2. Eye signs – Schirmer’s test <5mm/5 min, Rose Bengal Staining (RBS)
3. Mouth symptoms
4. Mouth signs (salivary ow, sialography, scintigraphy)
5. Labial gland biopsy (focal inltrative replacing acini)
6. Auto-antibodies (AABs) – SSA (anti-Ro), SSB (anti-La), RF,ANA
DOI: 10.1201/9781003156895-5 47
t.me/Dr_Mouayyad_AlbtousH
48 Classifications and Lists in Oral and Maxillofacial Surgery
https://t.me/med1917
SJÖGREN’S DIAGNOSIS CRITERIA – AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) 2012
e following list outlines the ACR (2012) criteria for the diag­nosis of Sjögren’s syndrome; all three are required for diagnosis.
1. Auto-antibodies
2. Labial gland biopsy
3. Rose Bengal stain
SURGERY FOR SALIVARY MALIGNANCY
e following list outlines surgical options for the management of salivary gland cancer.
Submandibular:
Gland excision + SND 1, 2a (+3 if high grade/risk – mucoepi­dermoid, SCC, carcinoma ex pleomorphic adenoma, anaplas­tic, >4cm) PLUS DXT (if >4cm, recurrent, advanced, adenoid cystic carcinoma)
Parotid:
Small, low-grade tumours managed surgically with supercial parotidectomy alone
Everything else requires total conservative parotidectomy + SND 1–3 (plus DXT as in the preceding)
Minor gland:
1cm WLE + SND (if not small low grade, plus DXT as in preceding)
t.me/Dr_Mouayyad_AlbtousH
Соседние файлы в папке @xirurgi_2025